Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of the Effect of the Topical Corticosteroid Fluocinonide in Patients on Endocrine Therapy for Either Breast Cancer or an Increased Risk for Breast Cancer With Symptoms of Vaginal Dryness and Dyspareunia

Next Previous
Trial Profile

Phase II Study of the Effect of the Topical Corticosteroid Fluocinonide in Patients on Endocrine Therapy for Either Breast Cancer or an Increased Risk for Breast Cancer With Symptoms of Vaginal Dryness and Dyspareunia

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 11 Aug 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fluocinonide (Primary)
  • Indications Atrophic vaginitis; Dyspareunia
  • Focus Therapeutic Use

Most Recent Events

  • 22 Oct 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
  • 15 Nov 2013 Planned end date changed from 1 May 2013 to 1 Nov 2014 as reported by ClinicalTrials.gov.
  • 01 Mar 2013 Planned end date changed from 1 Jan 2013 to 1 May 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top